MGI's DNBSEQ-T7 Powers YUCEBIO to Accelerate the Development of Clinical Application of Tumor Immunodiagnosis and Treatment
In 2019, MGI and YUCEBIO reached a strategic cooperation agreement “Over the last two decades, the field of oncology genomics has witnessed phenomenal growth that wouldn’t have been possible without the joint efforts from the oncology clinical genomic testing service companies. YUCEBIO is one of the leading companies in the field of tumor immunotherapy in China. We started our cooperation in 2018. We have witnessed the rapid development of YUCEBIO in the past two years, and we are glad ...